
    
      This is a Phase I, single-center, randomized, double-blind, placebo-controlled, two period,
      ascending dose, cross-over study to assess safety and PK of two doses of PT010 in healthy
      adult subjects of Japanese descent. Safety and PK will be assessed following a single dose
      and during twice-daily (BID) chronic dosing for 7 days.
    
  